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Abstract
Serum galactomannan (GM) antigen detection is not recommended for deﬁning invasive aspergillosis (IA) in children undergoing aggres-
sive chemotherapy or allogeneic haemopoietic stem cell transplantation (HSCT). The ability of the GM test to identify IA in children
was retrospectively evaluated in a cohort of children. Test performance was evaluated on samples that were collected during 195 peri-
ods at risk of IA. Proven IA was diagnosed in seven periods, all with positive GM test results (true positives, 4%), and possible IA was
diagnosed in 15 periods, all with negative GM test results (false negatives, 8%). The test result was positive with negative microbiologi-
cal, histological and clinical features in three periods (false positives, 1%), and in 170 periods it was negative with negative microbiologi-
cal, histological and clinical features (true negatives, 87%). The sensitivity was 0.32 and the speciﬁcity was 0.98; the positive predictive
value was 0.70 and the negative predictive value was 0.92. The efﬁciency of the test was 0.91, the positive likelihood ratio was 18.3,
and the negative likelihood ratio was 1.4. The probability of missing an IA because of a negative test result was 0.03. Test performance
proved to be better during at-risk periods following chemotherapy than in periods following allogeneic HSCT. The GM assay is useful
for identifying periods of IA in children undergoing aggressive chemotherapy or allogeneic HSCT.
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Introduction
Invasive aspergillosis (IA) is an infrequent, but severe, oppor-
tunistic infection in children undergoing antineoplastic che-
motherapy or haemopoietic stem cell transplantation
(HSCT) [1–13]. Serum galactomannan (GM) antigen detec-
tion has been suggested as a possible microbiological assay
for deﬁning probable cases of IA in immunocompromised
hosts, but it is not recommended for deﬁning IA in children
[14,15], because of the unreliability of the test in this patient
population [14,16]. To date, only two paediatric series
involving large numbers of patients or serum samples have
been reported [17,18].
The aim of the present study was to evaluate the perfor-
mance of GM antigen detection as a diagnostic tool for iden-
tifying IA during periods of risk for this complication in a
cohort of children undergoing antineoplastic chemotherapy
or HSCT.
Materials and Methods
We retrospectively evaluated the clinical characteristics of a
cohort of children receiving antineoplastic chemotherapy or
undergoing HSCT at the Department of Paediatric Haemato-
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logy and Oncology of the ‘G. Gaslini’ Children’s Hospital,
Genoa, Italy, and tested for the presence of serum GM antigen
in the period 1999–2005. In this patient population, the test
was routinely performed in all patients who presented at least
one of the following clinical conditions associated with an
increased risk of IA or a clinical picture suggestive of IA: (i)
persisting febrile neutropenia (fever not responding to 5–
7 days of broad-spectrum antibiotics in a persistently neu-
tropenic subject); (ii) severe acute (grade ‡2) or chronic
extensive graft-versus-host disease (GvHD); (iii) corticoste-
roid therapy at doses ‡1 mg/kg per day with prednisone or an
equivalent for a period ‡1 week) clinical features suggestive of
IA (sudden onset of clinical and radiological signs suggestive of
aspergillosis) [15]. Because risk factors for IA may be present
throughout the period of antineoplastic treatment or after
allogeneic HSCT [19,20], we adopted a pragmatic approach,
and considered the diagnosis of IA in different periods of risk,
identiﬁed by the availability of at least two consecutive sam-
ples for GM testing within 1 week. Periods at risk occurring in
the same patient were considered to be different if separated
by more than 4 weeks. Periods of risk were then stratiﬁed
according to the various treatment phases, as follows: (i)
aggressive chemotherapy (including standard chemotherapy
or megatherapy followed by autologous HSCT); and (ii) post-
allogeneic HSCT. During the study period, all cases of invasive
mycoses were prospectively collected and classiﬁed according
to the European Organization for Research and Treatment of
Cancer/Mycoses Study Group criteria [14,15].
GM detection was performed with the Platelia Aspergillus
test (Bio-Rad, Paris, France), following the manufacturer’s
recommendations. Results were expressed as an index of
positivity. The test result was deﬁned as positive when the
GM index cut-off (GM-I = sample optical density/cut-off
serum optical density) was >0.7 with a single test (static cut-
off), or between 0.5 and 0.7 with at least two consecutive
serum samples (dynamic cut-off), according to the deﬁnitions
adopted during the study period [21].
General management of patients
None of the patients received primary antifungal chemopro-
phylaxis against Aspergillus. The combination of a b-lactam and
an aminoglycoside or monotherapy with a b-lactam active
against Pseudomonas (including piperacillin–tazobactam) was
used to treat infectious complications on the basis of clinical
features and microbiological documentation. Weekly chest
computed tomography scans were performed in persistently
febrile neutropenic patients or in the presence of clinical signs
of respiratory tract infection. Empirical antifungal therapy,
mainly with liposomal amphotericin B, was administered to
high-risk patients with persistent febrile neutropenia [22].
Statistical analysis
In this exploratory study, all cases of invasive disease (e.g.
pneumonia) with absence of histological or microbiological
documentation and negative GM test results, i.e. cases of
‘possible’ IA, were arbitrarily classiﬁed as ‘false negatives’,
postulating the worst performance of the test. Histologically
documented cases with identiﬁcation of ﬁlamentous fungi
never growing in culture and positive GM test results were
classiﬁed as ‘probable’ IA, and cases of invasive disease
without histological documentation and with a positive GM
test result as the only ‘mycological criterion’ were excluded
from the analysis. Finally, the clinical records of patients
with a positive GM test result in the absence of clinical or
radiological ﬁndings suggestive of IA were retrospectively
evaluated in order to identify the presence of drugs, food
or other conditions, such as intestinal GvHD, that might
have affected the test results. Because of the possibility that
the positive GM test result could, in any case, indicate an
occult IA, the follow-up of these patients was prolonged
until December 2007. As piperacillin–tazobactam has been
reported to be the most frequent cause of false-positive
GM test results, the false-positive rate of the test was cal-
culated with inclusion and exclusion of periods with false-
positive results attributable to piperacillin–tazobactam [17].
All of the analyses in which the test performance was eval-
uated were performed after exclusion of the periods with
false-positive test results attributable to piperacillin–tazobac-
tam. These included sensitivity, speciﬁcity, positive predic-
tive value (PPV), negative predictive value (NPV), efﬁciency
(i.e. the correct classiﬁcation rate), and likelihood ratio
(i.e. the probability that the test results might increase or
decrease the pre-test probability of the disease) [23–25].
We also calculated the probability of missing a diagnosis
because of a negative GM result by applying the following
equation:
Prevalence · (1 ) sensivitity)/
Prevalence · (1 ) sensivitity) + [(1 ) prevalence) ·
speciﬁcity]
Because this parameter, like the PPV and NPV, may vary
with the prevalence of the disease [23,26], we also evaluated
the PPV, NPV and probability of missing a diagnosis using the
sensitivity and speciﬁcity that we obtained with our data and
the lowest and highest prevalence of IA reported in children
[1,3,5,8,10–13,17,27–29]. Statistical analyses were performed
using InStat version 3.0a for Macintosh (GraphPad Software,
San Diego, CA, USA), and the Dag_Stat98.xls spreadsheet
running on Microsoft Excel 2004 for Macintosh (Microsoft
Corp., Seattle, WA, USA).
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Results
During the study period, 1812 serum samples for Aspergillus
GM antigen detection were obtained from 119 patients with
a median age of 9.5 years (range, 1 month to 20 years); 14
samples (0.8%) were excluded because they were not fol-
lowed by another sample within 1 week, and therefore did
not identify a period of risk. The remaining 1798 samples
identiﬁed 210 periods of risk, with a median of one period
per patient (range, 1–9). The median duration of these peri-
ods was 15 days (range, 2–193 days), with a median of ﬁve
samples (range, 2–67) per period. Table 1 shows the number
of periods of risk by treatment phase of the underlying dis-
ease. A proven/probable IA was diagnosed in seven periods
(3%): two pneumonias due to Aspergillus fumigatus, and ﬁve
pneumonias due to ﬁlamentous fungi never growing in cul-
ture, all with positive GM test results. The GM test also
yielded positive results in four (2%) periods in the presence
of clinical and radiological ﬁndings suggestive of pulmonary
IA, but without any other microbiological or histological
proof. Clinical and radiological features were suggestive of IA
in 15 (7%) other periods, but no histological or microbiologi-
cal proof could be obtained. A total of 40 samples (2.2% of
all samples evaluated) with false-positive GM test results
were observed in 14 (false-positive rate, 7%) periods occur-
ring in 12 patients with a median age of 9 years (range, 2–
17 years). Administration of piperacillin–tazobactam was
identiﬁed as the cause of the false-positive test result in 11
of these, and their exclusion yielded a false-positive rate of
1.5%. The remaining three (1.4%) periods with a false-posi-
tive test result were observed in one patient with severe
intestinal GvHD following allogeneic HSCT who was receiv-
ing total parenteral nutrition, but no oral feeding and no
intravenous piperacillin–tazobactam. These three periods
were interspersed with other periods of negative GM test
results, for a total of 41 weeks of follow-up. The patient
underwent repeated extensive diagnostic and clinical work-
ups, but IA was never documented. Five years after the last
positive GM test result, the patient is alive, in good clinical
condition, and has no IA. No sign of IA was observed in the
other patients with false-positive GM test results during fol-
low-up. Finally, no clinical or radiological signs suggestive of
IA were present in 170 (81%) periods with negative GM test
results.
The four periods with positive GM test results in the
presence of clinical features suggestive of IA but in the
absence of other microbiological or histological documenta-
tion, and the 11 periods of false-positive GM test results
related to piperacillin–tazobactam, were excluded from all
further analyses.
Evaluation of the GM test performance for the diagnosis of
IA
The performance of the GM test was therefore evaluated in
195 (93%) of the periods at risk, with seven proven/probable
IA cases with positive GM test results (true positives, 4%),
15 possible IA cases with negative GM test results (false neg-
atives, 8%), three periods with positive test results with neg-
ative microbiological, histological and clinical features (false
positives, 1.5%), and 170 periods with negative test results
and negative microbiological, histological and clinical features
(true negatives, 87%). Table 2 summarizes the performance
of the GM test by the treatment phases of the underlying
disease. Overall, the test showed poor sensitivity (0.32), but
good speciﬁcity (0.98), with similar results being obtained in
the various phases of antineoplastic treatment. As regards
the predictive values, the overall PPV proved to be accept-
able (0.70), but it was poor (0.40) after allogeneic HSCT,
and very high after aggressive chemotherapy (1.00). On the
other hand, the NPV was always ‡0.90, as was the efﬁciency
of the test (Table 2). The overall positive likelihood
ratio was 18.3, but it was not evaluable in periods follow-
ing aggressive chemotherapy, because of the absence of
TABLE 1. Underlying diseases and phases of therapy in 210 periods of risk for invasive aspergillosis in 119 immunocompro-
mised children
Underlying disease No. of patients Periods at risk
Phases of therapy
Aggressive
chemotherapy
Allogeneic
HSCT
Acute lymphoblastic leukaemia/non-Hodgkin’s lymphoma 47 81 47 34
Acute non-lymphoblastic leukaemia 26 56 34 22
Juvenile chronic lymphoblastic leukaemia/myelodysplasia 10 15 1 14
Solid tumour 23 34 28 6
Non-malignant haematological disease 13 24 0 24
Total 119 210 110 100
HSCT, haemopoietic stem cell transplantion.
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false-positive test results in this subgroup, and it was found
to be acceptable (7.7) after allogeneic HSCT. Finally, the
probability of missing a diagnosis because of a negative GM
test result was 0.03 (with a 4% prevalence of IA). In particu-
lar, it was 0.03 after aggressive chemotherapy (5% prevalence
of IA) and 0.01 after allogeneic HSCT (2% prevalence of IA).
In a further analysis, we calculated the probability of miss-
ing a diagnosis because of a negative GM test result and the
predictive values of the test according to the prevalence of
IA reported in children with cancer (Table 3). Even in this
analysis, the test presented an overall very good NPV (with
the lowest value, 0.84, after allogeneic HSCT), although not
a good PPV. The risk of missing a case because of a negative
GM test result was highest after allogeneic HSCT in the
presence of the highest prevalence of IA.
Discussion
We evaluated the performance of the Aspergillus GM test for
the diagnosis of IA on 1812 serum samples obtained from
119 children undergoing aggressive chemotherapy or alloge-
neic HSCT during 210 periods of risk for this complication.
Overall, the performance of the test was found to be
good with regard to speciﬁcity and NPV, with high values
and narrow 95% CIs, but the speciﬁcity and PPV were not
good, with low values and wide 95% CIs. These results are
consistent with other studies in both children and adults
[17,18]. A recent, wide meta-analysis of the performance of
the GM test in the diagnosis of IA in immunocompromised
patients [23] revealed worse results in children than in
adults. However, this meta-analysis included few paediatric
studies, with low numbers of children enrolled in all but one
of them [18]. This may have biased the results, especially
considering the low prevalence of IA in children with cancer
or undergoing allogeneic HSCT [30]. Our results seem to
conﬁrm this hypothesis, even if it must be noted that, in gen-
eral, the performance of the test was better in periods fol-
lowing aggressive chemotherapy than in those following
allogeneic HSCT, even though speciﬁcity and NPV were
always very good, with high mean values and narrow
95% CIs. We also evaluated the likelihood ratio of the test,
i.e. the probability that the test result will increase or reduce
the pretest probability of the target disease [25]. Also, the
usefulness of this test is affected by the prevalence of the
disease. The prevalence of proven IA among our patients
(i.e. the pre-test probability) was only 4%. Overall, the posi-
tive likelihood ratio was high (18.3), indicating the relevance
of the test for the diagnosis of IA, and even though its
95% CI was wide, the fact that the lower limit was 5.1T
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indicates that a positive test result increases by at least ﬁve
times the pre-test probability that IA is present [25]. How-
ever, again, in periods following HSCT the test showed the
worst performance, as a 7.7 likelihood ratio is considered to
give a moderate shift from pre-test to post-test probability,
with a wide 95% CI with the lower limit approaching the
value of 1 [25]. Taking into account that the low prevalence
of IA in children may inﬂuence studies on the performance
of the GM test, we also evaluated the performance of our
results using the prevalence of IA reported in the most
recent paediatric literature, but the results did not change
signiﬁcantly. Finally, we also calculated the probability of
missing an episode of IA because of a negative GM test
result, considering both the prevalence that we observed in
our study and the prevalence reported in the paediatric liter-
ature. This probability was low in patients receiving aggres-
sive chemotherapy, whereas it increased in the presence of
the highest prevalence of IA, especially after allogeneic
HSCT. This is a peculiar aspect of our study that has never
been analysed in this setting [17,23], and our results cannot
therefore be compared with others, but may only be used
for future comparisons.
One last comment concerns the false-positive results.
After exclusion of periods with false-positive results clearly
attributable to piperacillin–tazobactam [17,23], some ‘unex-
plained’ false positives were still observed in risk periods
following allogeneic HSCT. This aspect has already been
reported and attributed, at least partially, to the presence
of GvHD [16,31,32]. Moreover, dietary contamination by
GM (especially formulated milk) has been indicated as
another possible cause of false-positive results in children
[16,31,33,34]. This aspect should be taken into account in
evaluating any individual patient, even though oral feeding is
not common in children during the phases of neutropenia,
because of the frequent occurrence of severe mucositis, or
when severe intestinal GvHD is present. In our series,
repeated periods of false-positive results were observed
only in one allogeneic HSCT recipient with severe intesti-
nal GvHD receiving total parenteral nutrition and no oral
feeding at the time of the false-positive results [35]. This
case must be considered to be a true false-positive result,
as the patient never developed IA during a 5-year follow-
up period, and it conﬁrms the possible role of intestinal
GvHD as a cause of false-positive GM antigen test results
after allogeneic HSCT, but not the possible role of oral
feeding.
In conclusion, the present study, together with other large
paediatric studies [17,18], suggests that the GM test may be
useful for the diagnosis of IA in children receiving aggressive
antineoplastic chemotherapy or undergoing allogeneic HSCT,T
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and that the GM test should be included in the diagnostic
criteria for IA in these patient populations.
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